A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia Clinical Trial

Official title:

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05732103
• Other study ID #: C22-11236
• Secondary ID: CTX-712-CL-02
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 25, 2023
• Est. completion date: April 2028

Study information

• Verified date: July 2023
• Source: Chordia Therapeutics, Inc.
• Contact: Laurie F Graham, RN, MSN
• Phone: (609) 608-2152
• Email: lgraham[@]theradex.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS).

The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by a confirmatory phase 1 expansion cohort where an additional approximately 10 patients will be treated with CTX-712 at the RP2D to gain further confidence in the selected dose level. After RP2D is determined, Drug-Drug-Interaction cohorts will be started.

The phase 2 part of the study will commence after the RP2D has been identified and confirmed and will evaluate therapeutic activity in R/R AML or R/R HR-MDS, in addition to confirmation of the safety profile.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: April 2028
• Est. primary completion date: April 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Age =18 years.

2. Diagnosis of AML, HR-MDS, or high marrow blast MDS/MPN (including CMML).

3. Prior treatment history must include 1-4 prior lines of therapy.

4. Adequate organ function evidenced by the following laboratory values:

Creatinine clearance (CL) =60 mL/min Total serum bilirubin < 1.5 × upper limit of normal (ULN) Alanine aminotransferase (ALT) Aspartate aminotransferase(AST) < 2.5 × ULN White blood cell count at the time of the first dose <10 k/µL

5. Eastern Cooperative Oncology Group performance status =2.

6. Female patients of childbearing potential must have a negative pregnancy test within 7 days before study treatment initiation and if sexually active, agree to use a highly effective form of contraception throughout their participation during study treatment and up to 4 months after the last dose of study drug

7. Male patients with female partners of childbearing potential must, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant.

Exclusion criteria:

1. Diagnosis of acute promyelocytic leukemia.

2. Isolated extramedullary relapse (phase 2 only).

3. Active central nervous system (CNS) leukemia.

4. History of other malignancy.

5. Any of the following cardiopulmonary abnormalities:

1. Myocardial infarction within six months prior to registration.

2. New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction < 50%.

3. A history of familial long QT syndrome.

4. Symptomatic atrial or ventricular arrhythmias not controlled by medications.

5. QTcF = 470 msec calculated according to institutional guidelines, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.

6. Known moderate to severe and clinically significant chronic obstructive pulmonary disease, interstitial lung disease and/or pulmonary fibrosis (e.g., requiring home oxygen therapy).

6. Pregnancy and/or lactation.

7. Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of CTX-712.

8. History of allogeneic organ transplantation (excluding cornea).

9. History of allogenic hematopoietic stem cell transplantation within 6 months of planned study treatment initiation and/or graft-versus host disease grade = 1 following allogenic hematopoietic stem cell transplantation.

10. History of or chimeric antigen receptor T-cell therapy or other modified T cell therapy.

11. Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus, hepatitis C virus, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness. Infections controlled with oral anti-infective agents, including prophylactic treatments, are allowed. Patient must be viral load negative.

12. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• CTX-712
CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.

Locations

Country	Name	City	State
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	Mayo Clinic Comprehensive Cancer Center	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Chordia Therapeutics, Inc.	Theradex

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to CTX-712.		Adverse events are collected from time of informed consent through 28 days after last dose of CTX-712.
Primary	Phase 1: The maximum tolerated dose MTD.	MTD is the dose producing <33% of dose-limiting toxicities.	Dose-limiting toxicities are collected during the first treatment cycle (28 days).
Primary	Phase 2: Complete remission rate, defined as the proportion of patients who achieve complete remission.		Measured from date of first dose to 28 days after last dose of CTX-712.
Secondary	Phase 1 and 2: Objective response rate, defined as the proportion of patients achieving a response.	For AML: CR, CRi, PR, MLFS. For MDS: CR, PR, mCR, HI.	Measured from date of first dose to 28 days after last dose of CTX-712.
Secondary	Phase 1 and 2: Duration of response.		Measure from documentation of tumor response to disease progression or death from any cause, whichever occurs first, assessed up to 24 months.
Secondary	Phase 1 and 2: Progression-free survival.		Measured from the date of initiating study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months.
Secondary	Phase 1 and 2: Overall survival.		Measured from the date of initiating study treatment to the date of death from any cause, assessed up to 36 months.
Secondary	Phase 1 and 2: Proportion of patients who transition to hematopoietic stem cell transplantation (HSCT).		Measured from the date of the last administration of CTX-712 until HSCT, or one year from the date of the start of administration of CTX-712.
Secondary	Phase 1: Maximum observed plasma concentration (Cmax) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed.		Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).
Secondary	Phase 1: Concentration before dose at steady state (Ctrough) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed.		Pharmacokinetic evaluation performed in treatment Cycles 1, 2 and 4 (cycle duration is 28 days).
Secondary	Phase 1: Area under the plasma concentration time curve (AUC) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed.		Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).
Secondary	Phase 1: Volume of distribution (Vd) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed.		Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).
Secondary	Phase 1: Elimination half-life of plasma concentration of CTX-712 at terminal phase (T1/2). Plasma samples for PK analyses will be collected at predetermined time points and analyzed.		Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).
Secondary	Phase 1: Clearance (CL) of CTX-712. Plasma samples for PK analyses will be collected at predetermined time points and analyzed.		Pharmacokinetic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).
Secondary	Phase 1: Measurement of the change in RNA splicing by CTX-712 in peripheral blood samples as pharmacodynamic markers. Peripheral blood samples for PD analyses will be collected at predetermined time points and analyzed.		Pharmacodynamic evaluation performed in treatment Cycle 1 (cycle duration is 28 days).